Results 31 to 40 of about 17,590 (203)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Biomarker Research, 2019
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical ...
Amandeep Aujla, Ravijot Aujla, Delong Liu   +2 more
doaj   +1 more source

Aberrant positivity for CD79a in erythroid lineage cells – a finding observed in a subset of re-staging bone marrow trephine biopsies after treatment

Haematologica, 2007
Aberrant expression of CD79a has been reported in neoplastic cells in peripheral T cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia (especially those with t(8;21)).
Rashpal Singh Flora, Finella Brito-Babapulle, Kikkeri N. Naresh   +2 more
doaj   +1 more source

Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement

Haematologica, 2022
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r).
Simon Bomken, Amir Enshaei, Edward C. Schwalbe, Aneta Mikulasova, Yunfeng Dai, Masood Zaka, Kent T.M. Fung, Matthew Bashton, Huezin Lim, Lisa Jones, Nefeli Karataraki, Emily Winterman, Cody Ashby, Andishe Attarbaschi, Yves Bertrand, Jutta Bradtke, Barbara Buldini, G.A. Amos Burke, Giovanni Cazzaniga, Gudrun Gohring, Hesta A. de Groot-Kruseman, Claudia Haferlach, Luca Lo Nigro, Mayur Parihar, Adriana Plesa, Emma Seaford, Edwin Sonneveld, Sabine Strehl, Vincent H.J. van der Velden, Vikki Rand, Stephen P. Hunger, Christine J. Harrison, Chris M. Bacon, Frederik W. van Delft, Mignon L. Loh, John Moppett, Josef Vormoor, Brian A. Walker, Anthony V. Moorman, Lisa J. Russell   +39 more
doaj   +1 more source

The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China

Frontiers in Oncology, 2022
Early T-cell precursor (ETP) lymphoblastic leukemia/lymphoma is a high-risk T lymphoblastic leukemia/lymphoma (T-ALL/LBL) subgroup. We performed a real-world multicenter study to explore the clinical characteristics and prognosis of adolescent and young ...
Jinyan Xiao, Zihong Cai, Hao Wang, Xuekai Li, Biqi Zhou, Yujie Liu, Ying Wang, Peipei Xu, Peipei Xu, Li Wang, Li Wang, Depei Wu, Liping Dou, Liping Dou, Hongsheng Zhou, Hongsheng Zhou, Yang Xu, Yang Xu   +17 more
doaj   +1 more source

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation

Frontiers in Oncology, 2023
ObjectiveThis study aims to compare the characteristics of early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) and non-ETP ALL patients and the outcomes of these patients after allogeneic hematopoietic stem cell transplantation ...
Juan Chen, Juan Chen, Juan Chen, Li Liu, Runzhi Ma, Aiming Pang, Donglin Yang, Xin Chen, Jialin Wei, Yi He, Rongli Zhang, Weihua Zhai, Qiaoling Ma, Erlie Jiang, Mingzhe Han, Sizhou Feng   +15 more
doaj   +1 more source

Acute lymphoblastic leukemia in infants: 20 years of experience

Jornal de Pediatria (Versão em Português), 2013
Objective: To analyze patients younger than 2 years with acute lymphoblastic leukemia, treated in the period between 1990 and 2010 in a state reference center.
Amanda Ibagy, Denise B. Silva, Jackline Seiben, Ana P.F.F. Winneshoffer, Tatiana E.J.B. Costa, Juliana S. Dacoregio, Imaruí Costa, Daniel Faraco   +7 more
doaj   +1 more source

Multi-Institution Review of Adult Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL)

Blood, 2015
Abstract Background: The Early T-cell precursor (ETP) variant of acute lymphoblastic lymphoma/leukemia (ALL) is a recognized high risk variant, recognized by the absence of CD1a, with aberrant myeloid antigen expression (CD13, CD33, CD117, and CD34), and frequent absence of CD4 or CD8. Treatment intensification may improve
Deniz Peker, Bijal D. Shah, Julio C. Chavez, Vamsi Kota, Amanda Redden Hathaway, Uma Borate, Ling Zhang   +6 more
openaire   +2 more sources

Aberrant synaptophysin expression in classic Hodgkin lymphoma

Diagnostic Pathology, 2022
Background Synaptophysin is an immunohistochemical marker for neuroendocrine differentiation and is widely used in pathologic diagnosis. Its expression in malignant lymphoma has not yet been described.
Soyoung Im, Jeong-A. Kim, Gyeongsin Park, Uiju Cho   +3 more
doaj   +1 more source

A Unique Case of Relapsed B-Acute Lymphoblastic Leukemia/Lymphoma as an Isolated Omental Mass

Case Reports in Hematology, 2014
B-acute lymphoblastic leukemia/lymphoma (B-ALL) is a neoplasm of precursor cells committed to the B-cell lineage. Extramedullary involvement is frequent, with particular predilection for the central nervous system, lymph nodes, spleen,
Kanchan Kantekure, Furha Cossor, Kenneth B. Miller, Monika E. Pilichowska   +3 more
doaj   +1 more source

Precursor B-cell lymphoblastic lymphoma of bone in children: A close mimicker of Ewing's sarcoma

Indian Journal of Medical and Paediatric Oncology, 2018
Precursor B-cell lymphoblastic lymphoma (LBL) occurring as a primary bone tumor is a rare clinical presentation in children, and data regarding this condition are limited to small case series or a few individual case reports.
Shwetha Seetharam, Priyakumari Thankamony, Priya Mary Jacob, Rekha Appukuttan Nair   +3 more
doaj   +1 more source